Ticagrelor Alone Versus Ticagrelor Plus Aspirin After a Heart Attack Treated With Medicine
Compares ticagrelor alone with ticagrelor plus aspirin in adults after a medically treated heart attack.
Plain-language title generated from the registry record
Registry title: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with a type 1 heart attack who will be treated with medicines alone, without a procedure to reopen the artery. It compares ticagrelor alone with ticagrelor plus aspirin for 12 months.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Hospitalized for a type 1 heart attack (myocardial infarction). A coronary angiogram has been done. Treatment is planned with medicines alone, without revascularization.
- Earlier treatment
- No hospitalization for a heart attack, PCI or CABG in the past 12 months. No other antiplatelet drug that must be continued.
Main reasons for not taking part
- Heart attack type 2 to 5, or unstable angina
- STEMI with an acute clot in a major heart artery
- Needs a long-term blood thinner taken by mouth, or another non-coronary reason for dual antiplatelet therapy
- Known allergy, intolerance or contraindication to aspirin or ticagrelor
- Spontaneous coronary artery dissection, confirmed or suspected
Read by machine on 9 November 2026.
Where in Canada
- Montreal Heart InstituteMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Montreal Heart Institute
- Trial code
- NCT07257198
- Record updated
- 10 March 2026
- Original description
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.Read full original descriptionShow less
Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Inclusion: Age ≥18 years; Hospitalized for type 1 MI, according to the 4th Universal Definition of MI; Coronary angiogram performed; Planned for medical management alone, without revascularization; Willingness to participate and to attend study visits; Expected life expectancy ≥12 months.
Exclusion: Concomitant indication for chronic oral anticoagulant; Concomitant non-coronary indication for dual antiplatelet therapy; Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician; Previous hospitalization for MI, PCI, or CABG within 12 months; Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI; Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.); Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor; Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel; Confirmed or suspected spontaneous coronary artery dissection; Unsuitability for either randomization treatment, based on the judgement of the treating physician.